Thermo Fisher Scientific recently announced a number of new partnerships in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.

Horizon Therapeutics has partnered with Invitae for its urea cycle disorder genetic (UCD) testing program, through which individuals who may have the rare genetic condition and their family members will receive testing at no charge.

Becton Dickinson reported today that its fiscal second quarter revenues decreased approximately 1 percent year over year.

Hologic announced today that the US Food and Drug Administration has cleared two of its infectious disease assays for common causes of a condition called vaginitis.

Roche today announced the CE-IVD marking of its Cobas MTB-RIF/INH test that detects mutations associated with resistance to the antibiotics rifampicin and isoniazid within tuberculosis DNA.

Investment Plan for Europe: Mobidiag secures EUR 25 million from EIB Funds will be used to accelerate the development and commercialisation of in vitro diagnostic solutions for infectious diseases.

Hologic reported after the close of the market on Wednesday that its fiscal second quarter revenues rose 4 percent year over year, driven by strong sales in its molecular diagnostics business.

Bio-Techne said today that its 2019 fiscal third quarter revenues rose 13 percent year over year, driven by double-digit organic growth in North America, Europe, and China.

Bio-Rad Laboratories reported after the close of the market Wednesday that its first quarter revenues rose a fraction of a percent year over year, besting Wall Street estimates.

Agilent Technologies reported after the close of the market on Tuesday that its fiscal second quarter revenues rose 3 percent year over year.

The US Food and Drug Administration has approved Qiagen's Therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for identifying which advanced breast cancer patients have PIK3CA mutations and are likely to respond to Novartis' alpelisib (Piqray).

Roche said recently that it has received US Food and Drug Administration 510(k) clearance for its Cobas TV/MG test for the detection of Trichomonas vaginalis (TV) and Mycoplasma genitalium (MG) DNA in symptomatic and asymptomatic patients.

PreludeDx said recently that the State of New York Clinical Laboratory Evaluation Program (CLEP) has approved its DCISionRT test

On May 20, 2019, Thermo Fisher Scientific announced that it is investing more than $50 million into its global bioproduction capabilities.

Velano Vascular has secured $10 million as the initial tranche of a growth financing to fuel commercialization and the launch of new vascular access solutions.